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The purpose of this manuscript is to provide a current concept review on the diagnosis and management of
diabetic foot infections which are among the most serious and frequent complications encountered in patients
with diabetes mellitus. A literature review on diabetic foot infections with emphasis on pathophysiology,
identifiable risk factors, evaluation including physical examination, laboratory values, treatment strategies
and assessing the severity of infection has been performed in detail. Diabetic foot infections are associated
with high morbidity and risk factors for failure of treatment and classification systems are also described.
Most diabetic foot infections begin with awound and once an infection occurs, the riskof hospitalization and
amputation increases dramatically. Early identification of infection and prompt treatment may optimize the
patient’s outcome and provide limb salvage.
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M
ore than 25 million people in the United States
are estimated to have diabetes mellitus (DM),
and 1525% will develop a diabetic foot
ulceration (DFU) during their lifetime (1, 2). Over 50%
of these ulcerations will become infected, resulting in
high rates of hospitalization, increased morbidity and
potential lower extremity amputation. Diabetic foot
infections (DFI) are one of the most common diabetes
related cause of hospitalization in the United States,
accounting for 20% of all hospital admissions (3). Read-
mission rates for DFI patients are approximately 40%
and nearly one in six patients die within 1 year of their
infection (4). In a large prospective study of patients with
DFU, the presence of infection increased the risk of
a minor amputation by 50% compared to ulcer patients
without infection (5).
The goal of this article is to review the pathophysiol-
ogy, identifiable risk factors, classification systems and
recommended evaluation of DFI.
Pathophysiology of diabetic foot infections
Several factors predispose diabetic patients to developing
a DFI, including neuropathy, vasculopathy and immuno-
pathy. Peripheral neuropathy occurs early in the patho-
genesis of diabetic foot complications and is considered
the most prominent risk factor for diabetic foot ulcers (6).
Diabetic patients with impaired protective sensation and
altered pain response are vulnerable to trauma and
extrinsic forces from ill-fitting shoewear. Motor neuro-
pathy causes muscle weakness and intrinsic muscle
imbalance leading to digital deformities such as ham-
mered or clawed toes. This results in elevated plantar
pressure due to metatarsophalangeal joint instability.
Autonomic dysfunction leads to changes in microvascu-
lar blood flow and arteriolar-venous shunting, diminish-
ing the effectiveness of perfusion and elevating skin
temperatures. With the loss of sweat and oil gland
function, the diabetic foot becomes dry and keratinized
which cracks and fissures more easily, leading to a portal
for infection. The most commonly utilized clinical
method of objectively diagnosing sensory neuropathy in
the foot and ankle setting involves the use of a Semmes-
Weinstein 10-g monofilament to assess for protective
sensation and a 128 Hz tuning fork for loss of vibratory
sensation (7).
Diabetic angiopathy is reported to be the most
frequent cause of morbidity and mortality in diabetic
patients (8). Macroangiopathy manifests as a diffuse
multisegmental involvement typically involving the infra-
popliteal vessels, and is also associatedwith compromised
collateral circulation. This is considered an atherosclero-
tic obstructive disease of large vessels, which leads to
peripheral arterial disease (PAD) of the lower extremities.
In a case control study of 112 hospitalized diabetic
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ently associated with a 5.5 fold increased risk for
DFI. Microangiopathy results in capillary basement
membrane thickening, altered nutrient exchange, tissue
hypoxia and microcirculation ischemia. Non-invasive
vascular studies such as the ankle brachial index
(ABI) is a reproducible and quantitative test for vascular
evaluation (10). An ABI value B0.90 or  1.30 is indica-
tive of PAD; with the latter significant for falsely elevated
values secondary to medial arterial calcification. An
increasing body of evidence supports the role of
toe pressures in the prediction of patients at risk for
ulceration and potential for wound healing, with an
absolute pressure  70 mmHg being normal. The toe
brachial index (TBI) may be substituted in those patients
with elevated ABIs secondary to lower extremity arterial
calcification. A normal TBI of  0.7 has been shown to
be superior to ABI for excluding the presence of PAD as
calcification is not usually present in digital vessels.
Another clinical test that can be performed, regardless
of arterial calcification in major pedal arteries, includes
transcutaneous oxygen (TcPO2) tension measurements.
Although not highly prognostic of wound healing
potential, TcPO2s are predictive of wound healing failure
at levels below 25 mmHg (11). Segmental pressure
volume recordings are also considered a secondary
tier approach for patients with non-compressible vessels.
The shape of the observed pulse waveform is analyzed to
evaluate the presence, location, and severity of vascular
disease. Lastly, skin perfusion pressure (SPP) utilizes a
laser Doppler measurement to indicate the presence or
absence of perfusion in the lower extremities through
cutaneous capillary circulation. Though SPP requires
specialized equipment, it has proven more sensitive than
other vascular tests for evaluation and diagnosis of PAD.
Immunopathy has been implicated in the diabetic
patient’s inherent susceptibility to infection as well as
the potential to mount a normal inflammatory response.
Impaired host defenses secondary to hyperglycemia
include defects in leukocyte function and morphologic
changes to macrophages. Bagdade et al. (12) demon-
strated that leukocyte phagocytosis was significantly
reduced in patients with poorly controlled diabetes,
and improvement of microbiocidal rates was directly
correlated with correction of hyperglycemia. Decreased
chemotaxis of growth factors and cytokines, coupled
with excess of metalloproteinases, impede normal wound
healing by creating a prolonged inflammatory state.
Fasting hyperglycemia and the presence of an open
wound create a catabolic state. Negative nitrogen balance
ensues secondary to insulin deprivation, caused by
gluconeogenesis from protein breakdown. This metabolic
dysfunction impairs the synthesis of proteins, fibro-
blasts and collagen, and further systemic deficiencies
are propagated which lead to nutritional compromise.
Research indicates impairment of the immune system
with serum glucose levels ]150 ml/dl (13). Patients
with diabetes tolerate infection poorly and infection
adversely affects diabetic control. This repetitive cycle
leads to uncontrolled hyperglycemia, further affecting the
host’s response to infection.
Risk factors for diabetic foot infections
Risk factors for DFU are clearly defined in current
literature; however, the body of evidence is not as great
for risk factors for DFI. In a large prospective study by
Lavery et al. (14), significant independent risk factors
for DFI included wounds that penetrated to bone,
wounds with a duration  30 days, recurrent wounds,
wounds with a traumatic etiology and the presence of
PAD. Foot wounds preceded all but one infection in their
151 patients, and the risk of developing an infection was
2,193 times greater in those subjects with a current
wound. Foot infection was a contributing factor for
hospitalization in 71.7% of their patients, and the risk
of hospitalization was 55.7 times greater for patients with
a DFI. The risk of amputation was 154.5 times greater
in patients with DFI compared to those without. Other
published studies associate neuropathy and history of
previous amputation as significant risk factors for infec-
tion. Socioeconomic, demographics, and other clinical
characteristics such as elevated body mass index (BMI)
and duration of diabetes have not been found to be
significantly associated with DFI (9).
Evaluation of the diabetic foot infections
Diabetic foot infections are among the most serious
and frequent complications encountered in patients
with DM. Diagnosing a DFI begins with clinical
suspicion through a comprehensive history and physical
exam, validated with a complete laboratory evaluation,
microbiology assessment and diagnostic imaging. The
diagnosis of a DFI is made on the basis of clinical
findings. According to the Infectious Disease Society of
America (IDSA) guidelines, infection is present if there is
obvious purulent drainage and/or the presence of two or
more signs of inflammation (erythema, pain, tenderness,
warmth, or induration) (15). Managing and treating DFI
can be challenging and should engage a multidisciplinary
team of experts including surgeons, infectious disease
specialists, hospitalists, diabetologists and nursing.
Patients present with a variety of complaints ranging
from local to systemic signs of infections. Local signs
of infection may include pain/tenderness, erythema,
edema, purulent drainage and new-onset malodor.
Systemic signs of infection include anorexia, nausea,
vomiting, fever, chills, night sweats, change in mental
status and a recent worsening of glycemic control. A
complete diabetic history should be obtained, including
duration of disease, insulin dependence, previous
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glycemic control. Past medical history should focus upon
related complications or comorbidities such as renal,
liver, cardiovascular disease, neuropathy and retino-
pathy. A current medication list should be obtained,
including past or current antibiotic use. Social history
must not be overlooked, including use of tobacco or
alcohol, quantity of weight-bearing and ambulation
level, diet and exercise and home support network. An
extensive review of systems should be used to evaluate the
severity of a potential infectious process.
Objective physical examination should begin by acquir-
ing vital signs, BMI and assessment of patient’s general
well-being. Hypothermia (B368C) or fever (388C), hypo-
tension, tachycardia, and tachypnea are considered signs
of severe infection and sepsis (15). However, patients with
DM may have an impaired neuroinflammatory response
and not manifest typical signs of infection. Armstrong
et al. (16) has documented that 82% of patients admitted
for osteomyelitis (OM) were afebrile on admission often
failing to mount a physiological response to infection.
Therefore, secondary signs of infection must be assessed
such as exudate production, delayed wound healing
and wound breakdown. Detailed wound descriptions
such as length, width and depth of the wound, color
and consistency of drainage, and character of wound base
(granular, fibrous or necrotic) should be documented.
The lower extremity can also be elevated for 5 min to
assess for dependent rubor since erythema associated
with infection typically does not resolve with elevation.
Osteomyelitis should be considered if bone is visible or
palpable in the base of an ulcer. In 1995, Grayson et al.
(17) demonstrated that a positive probe to bone test had
a sensitivity of 66% and specificity of 85% in diagnosing
OM in a cohort of hospitalized patients. Lavery et al.
(18) reported that a negative probe to bone test was a
stronger predictor for the absence of bone infection with
a negative predictive value of 98% compared to their
positive predictive value of only 57%. Shone et al. (19)
also found a lower positive predictive value of 53% and
emphasized the importance of the prevalence of osteo-
myelitis in the population being studied. The major
difference between the populations studied by Grayson,
Lavery and Shone was the prevalence of OM. Grayson’s
patients were hospitalized with infection while Lavery
and Shone studied patients in the outpatient setting.
A thorough vascular assessment is critical in the evalua-
tion of DFI. The extent and nature of edema should be
documented, along with documentation of lower extre-
mity pulses and capillary fill time. A hand-held Doppler
should be used for patients with faint or non-palpable
pedal pulses. Acquiring an ABI has proven to be a
reliable and simple exam to evaluate PAD. Falsely
elevated ABI values may warrant more vascular studies
such as those discussed earlier. If there is a high degree
of clinical suspicion of PAD, vascular consultation and
angiography should be considered, as an intervention
may be warranted in patients with ischemic infections.
The neurological exam should include testing for sensory,
motor and autonomic neuropathy including evaluation
of the Achilles reflex. Foot deformity, osseous promi-
nences, range of motion and gait abnormalities should
be documented.
Plain film radiography is important for the initial
assessment for evaluation of infection of soft tissue
and osseous structures, deformity and foreign bodies.
Soft tissue emphysema represents an emergent situation
and must be treated immediately. Osteomyelitis appears
as permeative radiolucencies, periosteal reaction and
destructive changes on plain films following 3050%
loss of bone mineralization (20). Plain films are con-
sidered 67% specific and 60% sensitive for OM (21).
Magnetic resonance imaging (MRI) is the most specific
and sensitive non-invasive test to evaluate OM and is
also useful for the evaluation of a probable abscess or
sinus tract formation (22). Bone scans, such as the white
blood cell labeled Indium-111, Technetium-99m HMPAO
and Sulfur Colloid Marrow Scan, may prove beneficial
between distinguishing acute and chronic infections,
with the latter useful for identifying OM from Charcot
neuroarthropathy by specifying bone marrow reactiva-
tion and neutrophil production (23).
Laboratory values are essential in DFI to establish
a baseline and assess on the response to treatment.
Armstrong et al. (16) found that fewer than 50% of
DFI patients mounted an elevated white blood cell
(WBC) in his study of 28 hospitalized DFI, with
the mean WBC count being 11.995.410
3 cells/mm.
A metabolic panel should also be ordered for the
assessment of renal function, electrolytes, acidosis, and
blood glucose level. Hemoglobin A1C levels provide a
barometer of glycemic control averaged over the previous
23 months. Acute phase reactants, including erythrocyte
sedimentation rate (ESR) and C-reactive protein level
(CRP) are markers of inflammation that are elevated in
response to inflammation, tissue injury and infections.
Recent evidence supports the use of ESR and CRP
for the evaluation of possible OM. Based on a study by
Butalia et al. (24), an ESR  70 mm/hr significantly
increases the probability of OM. Fleischer et al. (25)
concluded a CRP  3.2 mg/dl was a useful marker for
differentiating OM from cellulitis. Akinci et al. (26)
studied acute phase reactants at admission and 1 week
following treatment in hospitalized patients with DFIs.
The authors found that baseline and post-treatment CRP,
ESR and WBC were significantly elevated in patients
who ultimately required amputation. These results sug-
gest that a prominent acute phase response after begin-
ning treatment, as demonstrated by post-treatment CRP
levels, was a strong predictor of treatment failure and
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and albumin, well known as determinants of nutritional
status, are also acute-phase proteins which are down
regulated during inflammatory states. Hypoalbuminemia
can result from decreased albumin production secon-
dary to protein malnutrition, defective synthesis due to
hepatocyte damage, deficient intake of essential amino
acids, increased loss through inadequate GI and renal
function and commonly through acute and chronic
inflammatory states (27). Akinci et al. (26) reported
DFI patients who required amputation had signifi-
cantly lower serum album compared to those patients
who did not require amputation. Nearly 30 years ago,
Dickhaut et al. (28) related protein-calorie malnutri-
tion to increased morbidity and mortality of patients
undergoing surgery. In his study of 23 diabetic patients,
those with a serum albumin level of  3.5 g/dl, healed
primarily following a Symes level amputation compared
to those patients who fared below the normal range (28).
To the best of our knowledge, no study has directly
correlated albumin or prealbumin levels with severity of
DFI although Lipsky et al. (29) demonstrated that lower
serum albumin levels were predictive of treatment failure
in the SIDESTEP study. The mean albumin in those
who had a favorable response was 3.8 g/dl compared to
3.5 g/dl in those who failed treatment. More research is
warranted to better assess the relationship of serum
albumin and prealbumin levels with DFI.
Diabetic foot ulcerations are colonized by pathogenic
bacteria that may predispose a susceptible patient to a
lower extremity infection, defined as invasion and multi-
plication of microorganisms in body tissues associated
with tissue destruction or host inflammatory response.
Once a colonized wound progresses to an infected wound,
microbiological analysis permits the appropriate selec-
tion of antimicrobial therapy. Deep tissue cultures have
remained the standard for assessing infection, and the use
of superficial swabs, especially in clinically uninfected
wounds is discouraged. Causative organisms are more
reliably detected in specimens that are obtained deep
rather than superficial swabs, as the latter will include
colonizing organisms that may cause false results (30).
In a study of 84 randomly selected hospitalized patients
with severe DFI, 83% of cultures demonstrated poly-
microbial flora with an average of 2.8 species per speci-
men and aerobic to anaerobic bacteria ratio of 3:1 (31).
The most frequent isolated organisms were Staphylococ-
cus aureus, Staphylococcus epidermidis, and Streptococcus
species. Among anaerobes, Peptostreptococcus magnus
and Bacteroides fragilis were noted. Calhoun et al. (32)
found that aerobic gram-positive cocci were the most
common organisms isolated from diabetic wounds in
various studies, especially DFI that were categorized as
mild to moderate. Cultures of limb-threatening infections
identified Staphylococcus aureus, group B streptococci,
enterococcus, and facultative gram-negative bacilli. Pseu-
domonas aeruginosa may be identified in macerated
wounds and obligate anaerobes may be present in
necrotic or gangrenous infections (15). Among hospita-
lized patients, the prevalence of methicillin-resistant
Staphylococcus aureus (MRSA) in DFI is 1530%
depending on the geography (33).
Assessing the severity of a DFI is important for
selecting an antibiotic regimen and route of drug admin-
istration, need for hospitalization and evaluating the
potential necessity of surgery with likelihood of amputa-
tion. A mild DFI may be treated with oral antibiotic
therapy in an outpatient setting, whereas a moderate to
severe infection can be limb- or life-threatening requiring
inpatient antibiotic therapy, fluid resuscitation and con-
trol of metabolic derangements. Properly classifying DFI
will serve as a clinical utility to appropriately identifying
treatment strategies and patient outcome.
Classification of diabetic foot infections
Several classification systems have been proposed and
utilized for the assessment of DFU and DFI. There is no
one universally accepted classification system. Most
systems employ a matrix of grades based upon depth
and size of wound. Only a few classification systems have
incorporated important parameters such as presence of
ischemia, neuropathy and severity of infection.
Wagner’s classification is one of the most widely used
and universally accepted grading systems for DFU,
consisting of six simplistic wound grades used to assess
ulcer depth (grades 05) (34) (Table 1). This classification
is limited by the inability to recognize ischemia and
infection as independent risk factors in all classification
grades (35). For example, this system only identifies the
most severe findings of peripheral vascular disease in
grades 4 and 5, not accounting for more subtle signs of
ischemia. Similarly, only grade 3 acknowledges the
presence of infection and OM, limited to only deep
wounds.
A more recently proposed and popularized DFU
classification is the University of Texas Health Science
Center San Antonio (UT) classification system (Table 2)
(35). This system incorporates a matrix structure of four
grades of wound depth with subgroups to denote the
Table 1. Wagner classiﬁcation system
0 Pre-ulcerative area without open lesion
1 Superficial ulcer (partial/full thickness)
2 Ulcer deep to tendon, capsule, bone
3 Stage 2 with abscess, osteomyelitis or joint sepsis
4 Localized gangrene
5 Global foot gangrene
Source: Adapted from Wagner (34).
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frank purulence and/or two or more local signs of
inflammation such as warmth, erythema, lymphangitis,
lymphadenopathy, edema, pain and loss of function
may be classified as ‘infected.’ Lower extremity vascular
insufficiency is made by a combination of one or more
clinical signs or symptoms of claudication, rest-pain,
absent pulses, dependent rubor, atrophic integument,
absence of pedal hair or pallor on elevation coupled
with one of more non-invasive values such as a TCPO2
B40 mmHg, ABI B0.8 or absolute toe systolic pressure
B45 mmHg. A study by Oyibo et al. (35) evaluated
194 DFU, utilizing both Wagner and UT classifications
to compare patient prognosis. Their results revealed
that the UT grade had a slightly greater association
with increased risk of amputation and prediction of
ulcer healing, and they concluded that this system a
greater predictor of clinical outcome than Wagner’s
classification.
The IDSA classification scheme includes four progres-
sive levels of infection based upon severity correlated to
clinical findings (15) (Table 3). This classification scale,
developed in 2004 and now widely accepted in many
academic and clinical circles, was later validated and
shown to predict clinical outcomes in a prospective
observational study by Lavery et al. (36). In their study
of 1,666 patients with DFI, there was an observed trend
toward a significant increase in hospitalization rates
and lower extremity amputation as it corresponded to
increased severity of infection. Mild infections are
characterized by B2 cm of erythema while moderate
infections have  2 cm of erythema. Severe infections are
associated systemic toxicity and/or metabolic instability.
One of the weaknesses of this classification is that it does
not adequately describe the local wound environment.
The IDSA classification system may further be supple-
mented with the UT classification system to incorporate
depth of ulceration and presence of ischemia (e.g. ‘the
patient presents with a UT 3B wound with an IDSA
category moderate infection’).
Treatment of diabetic foot infections
The IDSA formulated guidelines and key recommenda-
tions for treatment of DFI stating that an empirical
antibiotic regimen should be implemented primarily on
the basis of infection severity and likely pathologic agents
(15). Optimally, definitive therapy should be based upon
culture and susceptibility analysis. The antibiotic regimen
should always include an agent active against gram
positive cocci with special attention for MRSA in high
risk patients. Previously treated or severe DFI should
include extended coverage for gram-negative bacilli and
Table 2. University of Texas Health Science Center San Antonio classiﬁcation system
01 2 3
A No open lesion Superficial Wound Tendon/Capsule Bone/Joint
B With infection With infection With infection With infection
C Ischemic Ischemic Ischemic Ischemic
D Infection/Ischemia Infection/Ischemia Infection/Ischemia Infection/Ischemia
Source: Adapted from (45).





on the Diabetic Foot
Wound without purulence or any manifestations of inflammation Uninfected 1
]2 Manifestations of inflammation (purulence or erythema, pain, tenderness,
warmth, or induration); any cellulitis or erythema extends 52 cm around
ulcer, and infection is limited to skin or superficial subcutaneous tissues; no
local complications or systemic illness
Mild 2
Infection in a patient who is systemically well and metabolically stable
but has ]2 cm; lymphangitis; spread beneath fascia; deep tissue abscess;
gangrene; muscle, tendon, joint, or bone involvement
Moderate 3
Infection in a patient with systemic toxicity or metabolic instability (e.g., fever,
chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis,
hyperglycemia, or azotemia)
Severe 4
Source: Adapted from Lavery et al. (36).
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wounds may require anti-anaerobic therapy. Cost of
therapy is also an important factor in selecting a
treatment regimen as well as consideration of potential
drug side effects, pharmacokinetics and bioavailability,
and frequency and route of administration. McKinnon
et al. (37) demonstrated that therapy with ampicillin/
sulbactam was similarly efficacious but significantly less
expensive than imipenem/cilastin for moderately severe
DFI secondary to lower drug and hospitalization costs.
The SIDESTEP study, a randomized, double-blinded,
multicenter trial of 586 patients with a moderate or severe
DFI, concluded the clinical and microbiological out-
comes of those patients treated with ertapenem were
equivalent to those treated with pipercillin/tazobactam
(29). This study suggests that the once daily dosed
ertapenem is advantageous in the DFI setting, despite
the fact that ertapenem does not cover most enterococci
or Pseudomonas aeruginosa, indicating these organisms
may only be contaminants in polymicrobial DFIs.
Optimal duration of antibiotic therapy has yet to be
defined based upon clinical studies. In general, moderate
and severe DFI are typically treated from 2 to 4 weeks of
intravenous (IV) antibiotic therapy with 46 weeks of
therapy for OM.
Surgical management of moderate to severe DFI is
often required and includes aggressive incision, drainage
and debridement of non-viable soft tissue and bone.
Multiple debridements are often necessary to provide
adequate drainage and control of infection. One study
reported amputation rates of 2.8, 46.2 and 77.7% in
mild, moderate and severe infections respectively (36).
The need for both minor (removal of a portion of foot
distal to the ankle joint) and major amputations (prox-
imal to the ankle joint) increased as the severity of
infection increased. Foot infections can extend proxi-
mally into the leg through the tarsal tunnel, resulting in
rapidly ascending limb and life threatening infection.
Early surgical treatment of DFI may reduce the need
for major amputations. Tan et al. (38) retrospectively
evaluated two groups of patients treated for DFI. Patients
in group 1 were treated with only IV antibiotic therapy,
while patients in Group 2 received IV antibiotic therapy
in addition to surgical management within the first
3 days of hospital admission. Patients in Group 2 were
found to have fewer above ankle amputations and a
6-day shorter hospital course than Group 1. With
severe life threatening DFI, open amputation or guillo-
tine procedures may take precedence to limb salvage
regardless of vascular status (39). It is preferable to
preserve as much distal viable soft tissue and bone as
possible when performing an amputation, potentially
allowing for delayed closure and functional weight
bearing.
Adjunctive therapies include the use of antibiotic
impregnated beads, application of negative pressure
wound therapy and hyperbaric oxygen treatment
(3941). Developing research continues to be directed at
therapies for improving the clinical outcome of patients
with DFI (42).
Predictors of treatment failure in diabetic foot
infections
Increased WBC and severe UT wound grades 2 and 3
were significant independent risk factors for clinical
failure in patients treated for a DFI in the SIDESTEP
study (43). Clinical failure was noted in 23% of
the patients with UT wounds 2B,D and 3B,D at baseline
compared with 11% with a wound stage of 0 or 1.
The mean WBC was 9,777 cells/mm
3 for those patients
who failed treatment compared to 7,933 cells/mm
3
for those with a favorable response. CRP and ESR
values greater than 9.1 and 54.4 respectively were
associated with treatment failure. A meta-analysis of
data from randomized controlled trials on DFIs observed
a treatment failure of 22.7% in 18 studies (44) Isolation
of MRSA was found to be a significant factor associ-
ated with treatment failure, although the presence
or absence of OM did not impact the outcome. In a
retrospective cohort study of the outcome of DFIs
treated conservatively, fever, increased serum creatinine,
prior hospitalization for DFI and gangrenous lesions
were independent factors associated with treatment
failure (42).
Conclusion
In 2010, 1.9 million Americans were newly diagnosed
with DM. (2). As this trend continues to rise, the
plausible threat of DFI becomes even more substantial
with dire financial consequences and severe limb and life
threatening outcomes. Understanding the pathophysiol-
ogy and promptly identifying risk factors for DFI is
essential. A thorough evaluation of DFI utilizing a
multidisciplinary team is recommended to achieve opti-
mal outcomes. It is important to accurate classify DFI to
guide treatment regimens, facilitate consistent commu-
nication between health care providers and predict
patient outcomes. The IDSA and UT classifications
provide a relatively simplistic and objective method of
classifying DFI. Prompt recognition and treatment of
DFI is mandatory to achieve a goal of maximal limb
salvage.
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